CA2934836C - Dosage regimen of ferric trimaltol - Google Patents
Dosage regimen of ferric trimaltol Download PDFInfo
- Publication number
- CA2934836C CA2934836C CA2934836A CA2934836A CA2934836C CA 2934836 C CA2934836 C CA 2934836C CA 2934836 A CA2934836 A CA 2934836A CA 2934836 A CA2934836 A CA 2934836A CA 2934836 C CA2934836 C CA 2934836C
- Authority
- CA
- Canada
- Prior art keywords
- ferric trimaltol
- iron
- ferric
- trimaltol
- anaemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201400171A GB201400171D0 (en) | 2014-01-06 | 2014-01-06 | Dosage regimen |
| GB1400171.3 | 2014-01-06 | ||
| GB1418708.2 | 2014-10-21 | ||
| GB201418708A GB201418708D0 (en) | 2014-10-21 | 2014-10-21 | Dosage regimen |
| PCT/IB2015/050098 WO2015101971A1 (en) | 2014-01-06 | 2015-01-06 | Dosage regimen of ferric trimaltol |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2934836A1 CA2934836A1 (en) | 2015-07-09 |
| CA2934836C true CA2934836C (en) | 2022-03-22 |
Family
ID=52432872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2934836A Active CA2934836C (en) | 2014-01-06 | 2015-01-06 | Dosage regimen of ferric trimaltol |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10179120B2 (https=) |
| EP (1) | EP3091974B1 (https=) |
| JP (2) | JP6556753B2 (https=) |
| KR (1) | KR102351422B1 (https=) |
| CN (2) | CN106413706A (https=) |
| AU (1) | AU2015204192B2 (https=) |
| BR (1) | BR112016015766A2 (https=) |
| CA (1) | CA2934836C (https=) |
| ES (1) | ES2785391T3 (https=) |
| IL (1) | IL246613B (https=) |
| SI (1) | SI3091974T1 (https=) |
| WO (1) | WO2015101971A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10179120B2 (en) | 2014-01-06 | 2019-01-15 | Iron Therapeutics Holdings Ag | Dosage regimen of ferric trimaltol |
| GB201418710D0 (en) * | 2014-10-21 | 2014-12-03 | Iron Therapeutics Holdings Ag | Dosage regimen |
| WO2017167963A1 (en) | 2016-03-31 | 2017-10-05 | Medical Research Council | Methods for producing ferric maltol compositions from ligand modified and ligand coated ferric hydroxides |
| WO2017167970A1 (en) | 2016-03-31 | 2017-10-05 | Medical Research Council | Methods for producing ferric maltol compositions from ferrous hydroxides |
| AU2017242905B2 (en) | 2016-03-31 | 2020-10-22 | Shield TX (UK) Limited | Methods for producing ferric maltol compositions from elemental iron |
| CA3019478C (en) | 2016-03-31 | 2024-02-13 | United Kingdom Research And Innovation | Ferric maltol compositions for use in the treatment or prevention of cancer and tumours |
| GB2553099A (en) * | 2016-08-19 | 2018-02-28 | Shield Tx Uk Ltd | Use |
| IT202100018578A1 (it) * | 2021-07-14 | 2023-01-14 | Indena Spa | Dispersione amorfa di maltolo ferrico e relativo processo di preparazione |
| CA3280511A1 (en) | 2024-07-18 | 2026-03-01 | Malian Biologicals Gmbh | Iron supplementation in affective disorders and/or post-traumatic stress disorder (ptsd) and/or serotonin-dependent diseases and iron supplementation in neurodevelopmental or psychiatric disorder |
| GB202414014D0 (en) | 2024-09-24 | 2024-11-06 | Shield Tx Uk Ltd | Use of ferric trimaltol in treating of preventing iron deficiency |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1150213B (it) * | 1982-03-02 | 1986-12-10 | Italfarmaco Spa | Derivati di ferro biodisponibile esenti da gastrolesivita',procentimento di preparazione e relative composizioni farmaceutiche |
| SU1676626A1 (ru) * | 1989-05-17 | 1991-09-15 | Тюменский государственный медицинский институт | Способ лечени железодефицитных анемий |
| RO113611B1 (ro) * | 1990-08-03 | 1998-09-30 | Asta Pharma Ag | Preparate solide de ifosfamida, administrate oral si procedeu de obtinere |
| AU6010696A (en) | 1995-06-10 | 1997-01-09 | Vitra Pharmaceuticals Ltd | Iron compounds, compositions, methods of making the same and uses thereof |
| ID18663A (id) * | 1996-04-12 | 1998-04-30 | Novartis Ag | Komposisi farmasi berlapis enterik |
| NZ328751A (en) * | 1997-09-16 | 1999-01-28 | Bernard Charles Sherman | Solid medicament containing an anionic surfactant and cyclosporin |
| US7135196B2 (en) | 2000-09-19 | 2006-11-14 | Vitra Pharmaceuticals Limited | Iron compositions |
| US20050118291A1 (en) * | 2003-09-10 | 2005-06-02 | Mian-Ying Wang | Formulations and methods for treating breast cancer with Morinda citrifolia and methylsulfonymethane |
| EP1877094A1 (en) * | 2005-05-03 | 2008-01-16 | Innozen, Inc. | Edible film for transmucosal delivery of nutritional supplements |
| EP1757299A1 (de) * | 2005-08-25 | 2007-02-28 | Vifor (International) Ag | Eisen(III)-Komplexverbindungen zur Behandlung von Eisenmangel-Zuständen bei Patienten mit chronisch-entzündlicher Darmerkrankung |
| US20070111936A1 (en) * | 2005-11-15 | 2007-05-17 | Vladimir Pak | Complex of alpha-fetoprotein and inducers of apoptosis for the treatment of cancer |
| GB0808835D0 (en) * | 2008-05-15 | 2008-06-18 | Vitra Pharmaceuticals Ltd | Therapeutic compositions |
| GB201101370D0 (en) | 2011-01-27 | 2011-03-09 | Iron Therapeutics Holdings Ag | Process |
| JP5856725B2 (ja) * | 2011-08-02 | 2016-02-10 | 和夫 酒井 | うつ病治療用または予防用医薬組成物 |
| US10179120B2 (en) | 2014-01-06 | 2019-01-15 | Iron Therapeutics Holdings Ag | Dosage regimen of ferric trimaltol |
| GB201418710D0 (en) | 2014-10-21 | 2014-12-03 | Iron Therapeutics Holdings Ag | Dosage regimen |
-
2015
- 2015-01-06 US US15/110,003 patent/US10179120B2/en active Active
- 2015-01-06 KR KR1020167021033A patent/KR102351422B1/ko active Active
- 2015-01-06 WO PCT/IB2015/050098 patent/WO2015101971A1/en not_active Ceased
- 2015-01-06 ES ES15701588T patent/ES2785391T3/es active Active
- 2015-01-06 SI SI201531165T patent/SI3091974T1/sl unknown
- 2015-01-06 JP JP2016562082A patent/JP6556753B2/ja active Active
- 2015-01-06 EP EP15701588.4A patent/EP3091974B1/en active Active
- 2015-01-06 BR BR112016015766A patent/BR112016015766A2/pt not_active Application Discontinuation
- 2015-01-06 CA CA2934836A patent/CA2934836C/en active Active
- 2015-01-06 CN CN201580005412.7A patent/CN106413706A/zh active Pending
- 2015-01-06 CN CN202111268204.XA patent/CN114010629A/zh active Pending
- 2015-01-06 AU AU2015204192A patent/AU2015204192B2/en active Active
-
2016
- 2016-07-05 IL IL246613A patent/IL246613B/en active IP Right Grant
-
2019
- 2019-04-05 JP JP2019072643A patent/JP2019131592A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019131592A (ja) | 2019-08-08 |
| IL246613B (en) | 2020-05-31 |
| CN114010629A (zh) | 2022-02-08 |
| US10179120B2 (en) | 2019-01-15 |
| JP2017501235A (ja) | 2017-01-12 |
| IL246613A0 (en) | 2016-08-31 |
| KR102351422B1 (ko) | 2022-01-13 |
| WO2015101971A1 (en) | 2015-07-09 |
| CA2934836A1 (en) | 2015-07-09 |
| AU2015204192A1 (en) | 2016-07-07 |
| SI3091974T1 (sl) | 2020-08-31 |
| JP6556753B2 (ja) | 2019-08-07 |
| ES2785391T3 (es) | 2020-10-06 |
| US20160324822A1 (en) | 2016-11-10 |
| EP3091974A1 (en) | 2016-11-16 |
| KR20160105499A (ko) | 2016-09-06 |
| BR112016015766A2 (pt) | 2017-08-08 |
| AU2015204192B2 (en) | 2020-03-26 |
| CN106413706A (zh) | 2017-02-15 |
| EP3091974B1 (en) | 2020-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2934836C (en) | Dosage regimen of ferric trimaltol | |
| KR960016582B1 (ko) | 위장장해의 치료 및 예방용 약제학적 조성물 | |
| JP2022070945A (ja) | 慢性腎臓病患者の治療におけるクエン酸第二鉄の使用 | |
| JP6828100B2 (ja) | 慢性腎臓病患者の心不全を軽減するためのクエン酸第二鉄 | |
| US20130225639A1 (en) | Altering pharmacokinetics of pirfenidone therapy | |
| CA2965096C (en) | Dosage regiment of ferric maltol | |
| KR960011772B1 (ko) | 개선된 디데옥시 퓨린 뉴클레오사이드 경구 투여 제제 | |
| JPWO2020080499A1 (ja) | 新規医薬組成物 | |
| RU2541092C2 (ru) | Бисглицинат-хелат железа для использования в пероральном лечении анемии у пациентов с целиакией | |
| GB2360706A (en) | Pharmaceutical compositions comprising ubiquinone 10 and/or succinic acid | |
| KR20160118234A (ko) | 만성 신장병의 진행 억제 또는 개선제 | |
| HK40065667A (zh) | 三麦芽酚铁的剂量方案 | |
| Obel et al. | Potassium supplementation versus bendrofluazide in mildly to moderately hypertensive Kenyans | |
| US12251400B2 (en) | Liquid concentrates of calcium and magnesium | |
| KR100631873B1 (ko) | 생체이용율이 증진된 알렌드론산 제제 | |
| TW202547454A (zh) | 治療前的尿白蛋白濃度在特定範圍之慢性腎臟病的治療用醫藥組成物 | |
| Ci | apozlni? |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20200106 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD Year of fee payment: 10 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241227 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241227 Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241227 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD Year of fee payment: 11 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251229 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251229 |